Everolimus plus exemestane as first-line therapy in HR+, HER2- advanced breast cancer in BOLERO-2

Breast Cancer Research and Treatment

Volumn 143, Issue 3, 2014, Pages 459-467

  Beck, J Thaddeus ^a   Hortobagyi, Gabriel N ^b   Campone, Mario ^c   Lebrun, Fabienne ^d   Deleu, Ines ^e   Rugo, Hope S ^f   Pistilli, Barbara ^g   Masuda, Norikazu ^h   Hart, Lowell ⁱ   Melichar, Bohuslav ^j   Dakhil, Shaker ^k   Geberth, Matthias ^l   Nunzi, Martina ^m   Heng, Daniel Y C ⁿ   Brechenmacher, Thomas ^o   El Hashimy, Mona ^p   Douma, Shyanne ^p   Ringeisen, Francois ^p   Piccart, Martine ^d  

^a Highlands Oncology Group   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c Institut de Cancérologie de l'Ouest René Gauducheau   (France)

^d JULES BORDET INSTITUTE   (Belgium)

^e AZ Nikolaas   (Belgium)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g Ospedale di Macerata   (Italy)

^h OSAKA NATIONAL HOSPITAL   (Japan)

ⁱ Florida Cancer Specialists   (United States)

^j PALACKÝ UNIVERSITY   (Czech Republic)

^k Cancer Center of Kansas   (United States)

^l Schwerpunktpraxis für Gynäkologische Onkologie   (Germany)

^m Hospital of Terni   (Italy)

ⁿ UNIVERSITY OF CALGARY   (Canada)

^o NOVARTIS PHARMA K K   (Japan)

^p NOVARTIS PHARMA AG   (Switzerland)

more..

Author keywords

BOLERO 2; Breast cancer; Everolimus; First line therapy; Metastatic disease; mTOR inhibition

Indexed keywords

AGED; AGED, 80 AND OVER; ANDROSTADIENES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, HORMONE-DEPENDENT; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SIROLIMUS;

EID: 84894045903     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2814-5     Document Type: Article

References (35)

1. Chumsri S, Howes T, Bao T, Sabnis G, Brodie A (2011) Aromatase, aromatase inhibitors, and breast cancer. J Steroid Biochem Mol Biol 125(1-2):13-22. doi: 10.1016/j.jsbmb.2011.02.001
2. Nadji M, Gomez-Fernandez C, Ganjei-Azar P, Morales AR (2005) Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. Am J Clin Pathol 123(1):21-27. doi: 10.1309/4WV79N2GHJ3X1841
3. Mohd Sharial MS, Crown J, Hennessy BT (2012) Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer. Ann Oncol 23(12):3007-3016. doi: 10.1093/annonc/mds200
4. Cardoso F, Costa A, Norton L, Cameron D, Cufer T, Fallowfield L, Francis P, Gligorov J, Kyriakides S, Lin N, Pagani O, Senkus E, Thomssen C, Aapro M, Bergh J, Di Leo A, El Saghir N, Ganz PA, Gelmon K, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Leadbeater M, Mayer M, Rodger A, Rugo H, Sacchini V, Sledge G, van't Veer L, Viale G, Krop I, Winer E (2012) 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast 21(3):242-252. doi: 10.1016/j.breast.2012.03.003
5. Cardoso F, Harbeck N, Fallowfield L, Kyriakides S, Senkus E (2012) Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23(Suppl 7):vii11-19. doi: 10.1093/annonc/mds232
6. Chia S, Gradishar W, Mauriac L, Bines J, Amant F, Federico M, Fein L, Romieu G, Buzdar A, Robertson JF, Brufsky A, Possinger K, Rennie P, Sapunar F, Lowe E, Piccart M (2008) Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 26(10):1664-1670. doi: 10.1200/JCO.2007.13.5822
7. Gnant M (2013) The role of mammalian target of rapamycin (mTOR) inhibition in the treatment of advanced breast cancer. Curr Oncol Rep 15(1):14-23. doi: 10.1007/s11912-012-0277-1
8. Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, Ferrero JM, Freyer G, Abadie-Lacourtoisie S, Eymard JC, Debled M, Spaeth D, Legouffe E, Allouache D, El Kouri C, Pujade-Lauraine E (2012) Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 30(22):2718-2724. doi: 10.1200/JCO.2011.39.0708
9. Boulay A, Rudloff J, Ye J, Zumstein-Mecker S, O'Reilly T, Evans DB, Chen S, Lane HA (2005) Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res 11(14):5319-5328. doi: 10.1158/1078-0432.CCR-04-2402
10. Gnant M (2012) Overcoming endocrine resistance in breast cancer: importance of mTOR inhibition. Expert Rev Anticancer Ther 12(12):1579-1589. doi: 10.1586/era.12.138
11. Novartis (2012) Afinitor (everolimus) prescribing information. Novartis Pharmaceuticals Corporation, East Hanover, NJ
12. Yardley DA, Noguchi S, Pritchard KI, Burris HA III, Baselga J, Gnant M, Hortobagyi GN, Campone M, Pistilli B, Piccart M, Melichar B, Petrakova K, Arena FP, Erdkamp F, Harb WA, Feng W, Cahana A, Taran T, Lebwohl D, Rugo HS (2013) Everolimus plus exemestane in postmenopausal patients with HR+ breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther 30(10):870-884. doi: 10.1007/s12325-013-0060-1
13. Burris HA III, Lebrun F, Rugo HS, Beck JT, Piccart M, Neven P, Baselga J, Petrakova K, Hortobagyi GN, Komorowski A, Chouinard E, Young R, Gnant M, Pritchard KI, Bennett L, Ricci JF, Bauly H, Taran T, Sahmoud T, Noguchi S (2013) Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial. Cancer 119(10):1908-1915. doi: 10.1002/cncr.28010
14. Campone M, Bachelot T, Gnant M, Deleu I, Rugo HS, Pistilli B, Noguchi S, Shtivelband M, Pritchard KI, Provencher L, Burris HA III, Hart L, Melichar B, Hortobagyi GN, Arena F, Baselga J, Panneerselvam A, Heniquez A, El-Hashimy M, Taran T, Sahmoud T, Piccart M (2013) Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study. Eur J Cancer 49(12):2621-2632. doi: 10.1016/j.ejca.2013.04.011
15. Gnant M, Baselga J, Rugo HS, Noguchi S, Burris HA, Piccart M, Hortobagyi GN, Eakle J, Mukai H, Iwata H, Geberth M, Hart LL, Hadji P, El-Hashimy M, Rao S, Taran T, Sahmoud T, Lebwohl D, Campone M, Pritchard KI (2013) Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2. J Natl Cancer Inst 105(9):654-663. doi: 10.1093/jnci/djt026
16. Noguchi S, Masuda N, Iwata H, Mukai H, Horiguchi J, Puttawibul P, Srimuninnimit V, Tokuda Y, Kuroi K, Iwase H, Inaji H, Ohsumi S, Noh WC, Nakayama T, Ohno S, Rai Y, Park BW, Panneerselvam A, El-Hashimy M, Taran T, Sahmoud T, Ito Y (2013) Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2. Breast Cancer. doi: 10.1007/s12282-013-0444-8
17. Pritchard KI, Burris HA III, Ito Y, Rugo HS, Dakhil S, Hortobagyi GN, Campone M, Csöszi T, Baselga J, Puttawibul P, Piccart M, Heng D, Noguchi S, Srimuninnimit V, Bourgeois H, Gonzalez Martin A, Osborne K, Paneerselvam A, Taran T, Sahmoud T, Gnant M (2013) Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2. Clin Breast Cancer 13(6):421-432. doi: 10.1016/j.clbc.2013.08.011
18. Baselga J, Campone M, Piccart M, Burris HA III, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366(6):520-529. doi: 10.1056/NEJMoa1109653
19. National Comprehensive Cancer Network (2013) NCCN Clinical Practice Guidelines in Oncology: breast cancer screening and diagnosis. Version 3.2013. http://www.nccn.org/professionals/physician-gls/pdf/breast-screening.pdf. Accessed 26 Sep 2013
20. Arbeitsgemeinschaft Gynäkologische Onkologie (2013) Diagnosis and treatment of patients with primary and metastatic breast cancer: guidelines of the AGO Breast Committee. www.ago-online.de. Accessed 26 Sep 2013
21. Pritchard KI, Gelmon KA, Rayson D, Provencher L, Webster M, McLeod D, Verma S (2013) Endocrine therapy for postmenopausal women with hormone receptor-positive her2-negative advanced breast cancer after progression or recurrence on nonsteroidal aromatase inhibitor therapy: a Canadian consensus statement. Curr Oncol 20(1):48-61. doi: 10.3747/co.20.1316
22. Bonneterre J, Buzdar A, Nabholtz JM, Robertson JF, Thurlimann B, von Euler M, Sahmoud T, Webster A, Steinberg M (2001) Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 92(9):2247-2258
23. Cohen MH, Johnson JR, Li N, Chen G, Pazdur R (2002) Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer. Clin Cancer Res 8(3):665-669
24. Paridaens RJ, Dirix LY, Beex LV, Nooij M, Cameron DA, Cufer T, Piccart MJ, Bogaerts J, Therasse P (2008) Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol 26(30):4883-4890. doi: 10.1200/JCO.2007.14.4659
25. Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, Verhoeven D, Pedrini JL, Smirnova I, Lichinitser MR, Pendergrass K, Garnett S, Lindemann JP, Sapunar F, Martin M (2010) Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 28(30):4594-4600. doi: 10.1200/JCO.2010.28.8415
26. Johnston SR, Kilburn LS, Ellis P, Dodwell D, Cameron D, Hayward L, Im YH, Braybrooke JP, Brunt AM, Cheung KL, Jyothirmayi R, Robinson A, Wardley AM, Wheatley D, Howell A, Coombes G, Sergenson N, Sin HJ, Folkerd E, Dowsett M, Bliss JM (2013) Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. Lancet Oncol 14(10):989-998. doi: 10.1016/S1470-2045(13)70322-X
27. Yardley DA, Ismail-Khan RR, Melichar B, Lichinitser M, Munster PN, Klein PM, Cruickshank S, Miller KD, Lee MJ, Trepel JB (2013) Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J Clin Oncol 31(17):2128-2135. doi: 10.1200/JCO.2012.43. 7251
28. Wolff AC, Lazar AA, Bondarenko I, Garin AM, Brincat S, Chow L, Sun Y, Neskovic-Konstantinovic Z, Guimaraes RC, Fumoleau P, Chan A, Hachemi S, Strahs A, Cincotta M, Berkenblit A, Krygowski M, Kang LL, Moore L, Hayes DF (2013) Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol 31(2):195-202. doi: 10.1200/JCO.2011.38.3331
29. Tabernero J, Rojo F, Calvo E, Burris H, Judson I, Hazell K, Martinelli E, Ramon y Cajal S, Jones S, Vidal L, Shand N, Macarulla T, Ramos FJ, Dimitrijevic S, Zoellner U, Tang P, Stumm M, Lane HA, Lebwohl D, Baselga J (2008) Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 26(10):1603-1610. doi: 10.1200/JCO.2007.14.5482
30. Dees EC, Carey LA (2013) Improving endocrine therapy for breast cancer: it's not that simple. J Clin Oncol 31(2):171-173. doi: 10.1200/JCO.2012.46.2655
31. ClinicalTrials.gov. S1207 hormone therapy with or without everolimus in treating patients with breast cancer. http://www.clinicaltrials.gov/ct2/show/ record/NCT01674140. Accessed 26 Sep 2013
32. Chavez-Mac Gregor M, Barlow WE, Gonzalez-Angulo AM, Rastogi P, Mamounas EP, Ganz PA, Schott AF, Paik S, Lew DL, Bandos H, Hortobagyi GN (2012) S1207: phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy ± one year of everolimus in patients with high-risk, hormone receptor-positive and HER2-neu negative breast cancer (NCT01674140). Presented at San Antonio Breast Cancer Symposium; December 4-8, 2012; San Antonio, TX, USA. Poster OT2-2-04
33. - primary breast cancer, free of disease after receiving 3 years of adjuvant hormone therapy. http://www.clinicaltrials.gov/ct2/show/NCT01805271. Accessed 26 Sep 2013
34. Bachelot T, Chabaud S, Martin A-L, Lemonnier J, Bliss J, Cameron D, Hardy Bessard A-C, Campone M, Andre F (2013) Everolimus plus adjuvant endocrine therapy in high risk breast cancer: the UNIRAD study. Presented at American Society of Clinical Oncology (ASCO); May 31-June 4, 2013; Chicago, IL, USA. Poster/abstract TPS653
35. + metastatic breast cancer (BOLERO-4). http://clinicaltrials.gov/ct2/show/NCT01698918?term= NCT+01698918&rank=1. Accessed 26 Sep 2013